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Abstract
Background: Antipsychotic are the cornerstone in the treatment of schizophrenia. They also have a number of
side-effects. Constipation is thought to be common, and a potential serious side-effect, which has received little
attention in recent literature.
Method: We performed a retrospective study in consecutively admitted patients, between 2007 and 2009 and
treated with antipsychotic medication, linking different electronic patient data to evaluate the prevalence and
severity of constipation in patients with schizophrenia under routine treatment conditions.
Results: Over a period of 22 months 36.3% of patients (99) received at least once a pharmacological treatment for
constipation. On average medication for constipation was prescribed for 273 days. Severe cases (N = 50), non-
responsive to initial treatment, got a plain x-ray of the abdomen. In 68.4% fecal impaction was found.
Conclusion: A high prevalence of constipation, often severe and needing medical interventions, was confirmed
during the study period. Early detection, monitoring over treatment and early intervention of constipation could
prevent serious consequences such as ileus.
Background
Antipsychotics are the cornerstone of the treatment of
schizophrenia and related psychotic disorders. There is
a growing interest in the physical co-morbidities and
somatic side-effects of these agents [1-6]. Constipation
is a well-known but poorly researched side-effect of
antipsychotics [7-9].
Recent reviews showed that constipation is prevalent
and can lead to severe consequences and even prema-
ture mortality [7,10].
Talley et al. evaluated the association between medica-
tion and constipation [11]. Antipsychotic users had a 1.9
higher risk to develop constipation compared to non-
users. Stanniland and Taylor reported rates of 1.5% to
25% compared to placebo [12].I nc l o z a p i n eu s e r sc o n -
stipation is among the top 4 reported side-effects with
prevalence rates ranging from 14 up 60% [13-15]. In
extreme cases this may lead to bowel obstruction and
paralytic ileus which, if not detected and treated early
may lead to premature mortality [14,16-18]. Palmer
et al. described 102 cases of severe gastrointestinal side-
effects on clozapine of which 28 were fatal [14]. Mortal-
ity on clozapine due to constipation could be higher
than that of agranulocytosis [7].
At our University Hospital an pharmacy audit in 2008
showed that at least 1 out of 3 adult patients with schizo-
phrenia were at least once treated for constipation during
hospitalization. In 2009 the total expenditure for medica-
tion for constipation exceeded 40,000 USD per year. As a
comparison this constituted 5 times the expenditure of
anticholinergic drugs for motor side-effects, 30% of the
cost of depot antipsychotics or 7% of the total cost of
antipsychotics [2,10].
The aim of the current study was to evaluate the pre-
valence and severity of constipation in routine treatment
in patients with schizophrenia.
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We performed a retrospective electronic record linking
study (medical records, pharmacy data, somatic data
and radiological data) on all admitted patients, both
inpatients and patients in day-hospitalization, between
June 2007 and March 2009, with a clinical DSM-IV
diagnosis of schizophrenia treated with antipsychotic
medication in a University Psychiatric Hospital, with a
regional Catchment area of 300,000 inhabitants. Patients
were only included if they were not treated with laxa-
tives at first inclusion.
There were no other in- or exclusion criteria. The
association between specific antipsychotics was not
assessed because of the retrospective nature of the study
and potential polypharmacy which could confound the
results.
Constipation was defined as have at least one new
prescription of a laxative.
Descriptive statistics were performed with statistical ana-
lysis software (SAS, Statistical Analysis System, Carey NC).
Patients had given informed consent for anonymous
data analysis and the study was approved by both the
local scientific and ethical committee.
Results
Over the 22 months observation period there were 371
admissions of 273 individual patients with schizophre-
nia. The mean age of the sample was 40.1 years (±13.5,
range 17 to 82) and 65.6% were male. The mean dura-
tion of admission (including day hospitalization) was
472 days (±1,073, median 99.3, range 0.02 to 6,291).
During the admissions there were 1,751 different pre-
scriptions of antipsychotics. The largest groups were
second generation antipsychotics (Table 1.). Over the
study period there were no major trends of change of
the relative distribution of individual drugs. There were
123 prescriptions of anticholinergic agents (89.4%
biperidene).
Ninety nine patients (36.3%) had at least 1 new phar-
macological intervention for constipation. In total 11
different interventions were recorded (Table 2.). The
most frequently used drugs were the macrogols 4,000
(30.6%) and 3,350 (22.5%) followed by the stimulant
laxative sodiumpicosulphate (25.4%). These 3 consti-
tuted 75% of all drugs used to combat constipation.
Over the study period 271 different treatments periods
were recorded in 99 patients. Of these 16% were treatments
with enemas, for constipation episodes non-responsive to
oral treatments. 68% of the constipation treatments lasted
longer than 1 week. Only enemas were prescribed for
shorter periods (mostly a single intervention). For lactulose
and macrogol 4,000 90% of prescriptions lasted longer than
a week. The mean duration of prescriptions, excluding
enemas, was 273 days (±603, median 49, range 1 to 4,854)
and was different for specific drugs (lowest for macrogol
4,000 195 days (±233, median 124, range 1 to 1,124), fol-
lowed by sodiumpicosulphate 307 days (±716, median 73,
range 1 to 3,766) and longest for macrogol 3,350 522 days
(±922, median 38, range 1 to 3,766)).
There were 114 referrals (N patients 54) to the
somatic department for additional treatment and follow-
up of constipation. In 89.5% of cases this resulted in
prescription of oral medication, 7.9% enemas and 8.8%
other interventions such as advice on diet, hydratation
and physical activity (multiple interventions possible).
Of the referred patients 92.6% (N = 50) were exam-
ined with a plain x-ray of the abdomen. A total of 99 of
x-ray examinations of the abdomen were registered.
Only in 5.1% (N = 5) were negative. In 26.5% (N = 26)
fecal accumulation was observed, while fecal impaction
was present in 68.4% (N = 68).
Discussion
This is the first study systematically evaluating the pre-
valence and severity of constipation in patients with
constipation under routine treatment conditions. Consti-
pation was highly prevalent and often required pharma-
cological intervention (36.3% of patients).
Hiele reported a prevalence of constipation between 2
and 28% in the Belgian general population [19]. In a
review on the prevalence of constipation in Europe
showed an average prevalence of 17.1% [20]. Other
population studies estimate signs and symptoms of
chronic constipation in 10 to 20% of individuals of a
general practice sample [11]. In all these studies the
higher prevalence rates were found in older people.
In our study with a younger population of patients
with schizophrenia constipation rates were higher than
Table 1 Prescription of antipsychotics (N prescriptions
and %)
Antipsychotic Product Frequency %
2
nd generation
(Atypical)
Aripiprazole (Abilify
®) 202 11.5
Clozapine (Leponex
®) 165 9.4
Risperidone (Risperdal
®) 223 12.7
Sertindole (Serdolect
®) 43 2.5
Quetiapine (Seroquel
®) 126 7.2
Amisulpride (Solian
®) 89 5.1
Olanzapine (Zyprexa
®) 204 11.7
1st generation
(Typical)
Low-potency 301 17.2
High-potency 209 11.9
Long-acting (Depot) Risperidone (Risperdal
Consta
®)
115 6.6
Typical depot 73 4.2
Total 1,751 100
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valence in patient samples may be even higher since we
identified constipation only in patients who were either
referred to the somatic department or who received
treatment for constipation.
Our study confirms the scarce literature on antipsycho-
tic associated constipation in patients with schizophrenia.
Additional risk factors in this patient group might be diet
and lack of exercise related [18,21]. Anticholinergic med-
ication can also induce gastrointestinal symptoms,
including constipation [7]. Schizophrenia as such and its
treatment with antipsychotics could be accompanied
with a higher discomfort or pain threshold, which could
be a reason why these patients report somatic complaints
later or less frequently [22,23]. This could lead to late or
under-diagnosis of constipation. Next to a higher pain
threshold negative symptoms could also be associated
with more indifference and problems with adequately
expressions of pain sensations [22,23].
Constipation was not only frequent but also severe.
This was confirmed by the long duration of constipation
treatment, of more than 250 days on average. The use
of enemas was not rare (16% of constipation treat-
ments). Constipation can lead to fecal impaction, result-
ing in bowel obstruction and perforation [7]. Multiple
cases with a fatal outcome have been reported as a
result of perforation, asphyxiation of fecal vomitus and
fecal impaction resulting in necrosis [18]. The severity
of constipation associated with antipsychotic drug use
was also confirmed in this study with the high rate of
fecal impaction, a risk factor for more severe and poten-
tially lethal complications [7]. A recent register-based
study focusing on cases of ileus in patients with schizo-
phrenia showed that both anticholinergic drugs and
antipsychotics with anticholinergic properties were asso-
ciated with fatal cases [24].
Given the potential severe consequences of constipa-
tion early detection, monitoring over the course of
treatment and early treatment are important. Side-
effects are an important reason for non-compliance and
constipation is also associated with poorer health related
quality of life [25]. Next to treatment with laxatives a
reduction of antipsychotic dose has been proposed in
the literature [26].
Limitations of this study are the retrospective design
relying on electronically recorded data and not direct
patient assessments. The study is mono-centric which
can impact on generalizability. We did not evaluate the
association between specific antipsychotic medication
and the prevalence nor incidence of constipation. No
data was available on constipation treatments prior to
the studied period. A last limitation is that no data was
collected on outpatients.
Future research should focus on predictors and the
effectiveness of preventive measures and the different
treatment options, as well as the underlying pharmaco-
logical mechanisms (e.g. predictors, differences between
antipsychotic agents, timing of onset of constipation).
Conclusions
Constipation associated with antipsychotic treatment is
frequent in patients with schizophrenia. It can be severe
when early detection fails. It leads to long-term pre-
scription of pharmacological interventions. Clinical staff
should be aware of this association and actively screen,
monitor and provide early treatment. Preventive action
with advice on diet, hydratation and adjustment of phy-
sical activity levels should be promoted.
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Table 2 Pharmacological treatment of constipation (N prescriptions and %)
Product 2007 2008 2009 Total period
Freq % Freq % Freq % Freq %
Bisacodyl + enema (bowel preparation enema like) 0 0 1 0.8 0 0 1 0.4
Ispaghula 1 1.4 1 0.8 0 0 2 0.7
Lactulose 2 2.7 8 6 2 3.1 12 4.4
Macrogol (bowel preparation enema like) 19 26 2 1.5 0 0 21 7.8
Macrogol 3,350 8 11 36 27 17 26.2 61 22.5
Macrogol 4,000 19 26 40 30 24 36.3 83 30.6
Sodiumpicosulphate 17 23.1 34 25.6 18 27.7 69 25.4
Senna 00001 1 . 510 . 4
Sodium phosphate (enema) 5 6.9 7 5.3 2 3.1 14 5.2
Soap enema 0 0 2 1.5 0 0 2 0.7
Water enema 2 2.7 2 1.5 1 1.5 5 1.9
Total 73 100 133 100 65 100 271 100
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